The start-up meeting took place in Madrid from 23 to 25 October.

The Gatekeeper consortium includes 43 partners from 13 Member States, featuring technological companies, research institutes or universities, healthcare suppliers and European and international networks focusing on technological innovation. Kronikgune, Osakidetza and Biocruces Bizkaia will represent the Basque Country. Funded by the Horizon 2020 programme, this study will last 42 months and will have a total budget of 21 million euros.

Gatekeeper‘s main goal is to provide an open, standard-based, interoperational and safe framework, which is available for all the agents, and create digital solutions for early detection and the development of personalised interventions. This will harness all the potential of new technologies and, especially IoT, to improve the social-healthcare services that are provided to an increasingly older population.

This initiative seeks to gain evidence in regards to care quality and healthcare results, and the massive use of data through Artificial Intelligence, Big Data and data analytics technologies for early detection of diseases and disabilities, understanding symptoms and early diagnosis, and lastly to facilitate continuous and personalised monitoring. As a result, Gatekeeper is expected to contribute to guarantee a healthier independent life for ageing populations. Its large-scale deployment shall involve nearly 40,000 elderly citizens from seven European regions: Basque Country and Aragon (Spain), Saxony (Germany), Greece, Puglia (Italy), Milton Keynes (United Kingdom), Cyprus and Poland.

Kronikgune and Osakidetza shall focus on piloting two cases: (i) intervention related to healthy lifestyles in the elderly population; and (ii) treatment of multimorbid and polymedicated patients. In the first case, they will implement analysis techniques to large quantities of data to address risk stratification and early detection and provision of digital coaching. In the second case, they will come up with innovative solutions to increase the treatment commitment of polymedicated patients and to avoid the adverse reactions deriving from the medication.

Funding of this project by the European Commission implies its commitment to innovation to face the challenges of the healthcare and social care system considering the progressive ageing of the population. If you wish to learn more, please visit